Instructions for refrigerated storage conditions of Pyrotinib/Areni

Pyrotinib Maleate (Pyrotinib Maleate) is an oral small molecule tyrosine kinase inhibitor for HER2-positive breast cancer. As a targeted therapy drug, its active ingredients are very sensitive to the storage environment, so correct storage is crucial to ensure drug efficacy and patient safety.

According to the drug instructions and information, Aerini should be kept sealed and stored in a dry place below 25°C, away from direct sunlight and high temperature and humidity. Sealing not only prevents moisture and oxygen in the air from damaging the chemical structure of the drug, but also prevents external microbial contamination from affecting the quality of the drug. Long-term exposure of drugs at room temperature may lead to degradation of active ingredients, reduce therapeutic efficacy, and even affect patient tolerance.

After opening the medicine, you need to pay more attention to the expiry date. Normally, Irene should be used within one month after opening to ensure drug activity and stability. During this time, keep the tablets away from moisture or heat, and keep them in a safe place out of the reach of children. Home refrigeration conditions do not require a strict cold chain, but excessive temperature fluctuations, such as frequent opening and closing of the refrigerator or close proximity to the freezer area, should be avoided.

In addition, the environmental temperature of drugs also needs to be strictly controlled during transportation, dispensing and use. Overseas research emphasizes that the chemical stability of oral targeted drugs is directly related to clinical efficacy and safety, so the entire circulation chain from production to patients should maintain standardized management. Regular pharmacies and hospitals usually cooperate with temperature control measures to ensure that every dose of medicine meets quality requirements.

In short, the refrigeration and dry storage of Aerini are not only the manufacturer’s recommended requirements, but also the basic measures to scientifically guarantee the efficacy. Following storage specifications and using opened medicines on time can help maintain drug activity, ensure sustained and stable therapeutic effects for HER2-positive breast cancer patients, and reduce the risk of drug efficacy fluctuations caused by improper storage.

Reference materials:https://www.drugs.com